CareDx
CareDx Q2 Revenues up 77 Percent
The company reported $74.2 million in total revenues for the quarter and said testing service revenues rose 79 percent year over year.
CareDx Q1 Revenues up 76 Percent
The company reported $67.4 million in total revenues for the quarter and said testing service revenues rose 89 percent year over year.
Bucking Downward 2021 Trend, 360Dx Index Rebounds 4 Percent in April
Of the 30 companies in the index, 18 firms saw their stock prices increase, while 12 saw their share prices decline.
Medicare Administrative Contractor Palmetto Finalizes Coverage of Molecular Testing for Organ Transplant Rejection
Under the policy, covered tests must provide information about active rejection status or cellular or antibody-mediated rejection status.
CareDx Acquires European Transplant Surveillance Software Firm BFS Molecular
The company uses next-generation sequencing data to track the health of transplanted organs and stem cells over time.
Feb 25, 2021
Feb 24, 2021
CareDx Q4 Revenues Up 64 Percent
Jan 21, 2021
CareDx Prices $175M Common Stock Offering
Oct 29, 2020
CareDx Q3 Revenues Up 58 Percent
Oct 7, 2020
CareDx Preliminary Q3 Revenues Up 57 Percent
Aug 4, 2020